Drug Profile


Latest Information Update: 19 Apr 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nattermann
  • Developer Nonindustrial source
  • Class Antiulcers; Choleretics; Cholic acids; Cytoprotectives; Gallstone therapies; Glycerophospholipids; Lipids; Phosphatidylcholines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 19 Apr 1996 A clinical study has been added
  • 11 Jul 1995 A clinical study has been added to the therapeutic trials section .
  • 21 Feb 1995 Discontinued-II for Atherosclerosis in Russia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top